Ketamine, Buprenorphine, Hopelessness, and Suicidal Suffering

In May 2026, Professor Alan Schatzberg and colleagues at Stanford reported findings that may alter how we understand suicidal thoughts and plans. Patients with major depressive disorder and clinically significant suicidal thoughts received a ketamine infusion followed by four weeks of ultra-low-dose buprenorphine or placebo. Those receiving buprenorphine maintained significantly greater reductions in suicidal ideation, with nearly 80% remaining responders after one month compared with less than half of those receiving placebo.

Most strikingly, buprenorphine appeared to sustain ketamine's anti-suicidal effects more strongly than its antidepressant effects. The findings support a growing view that suicidal suffering reflects disturbances in emotional pain, reward processing, and hopelessness—not just depression. Suicidal suffering may only partially overlap with depression.

The study presents a new and important therapeutic strategy. However, it may also represent the return of the opioid hypothesis proposed nearly half a century ago. Long before ketamine, neuroimaging, and modern theories of reward dysfunction, investigators at the National Institute of Mental Health (NIMH) suggested opioid systems might play a central role in depression and suicidal suffering. The Stanford findings may be the clearest clinical validation of that idea.

During the late 1970s, a small group of investigators—Frederick Goodwin, David Pickar, Irl Extein at NIMH, and myself—began exploring whether endogenous opioid dysfunction might contribute to depressive illness.

The hypothesis emerged shortly after the discovery of endorphins and other opioid peptides. These molecules were known to regulate pain, reward, motivation, stress responses, attachment, and neuroendocrine function. The NIMH group reasoned they might also modulate mood and emotional suffering.

Early evidence came from a prolactin challenge study in 1980. Goodwin's NIMH group demonstrated that depressed patients exhibited a markedly blunted prolactin response to morphine compared with healthy controls. Because opioid receptor activation normally stimulates prolactin release, the findings suggested impaired endogenous opioid function in severe major depression. The study proposed that depression might also involve disturbances in systems regulating reward, attachment, motivation, and emotional pain.

When Prozac and other SSRIs transformed psychiatric practice in the 1980s and 1990s, this opioid hypothesis faded from view.

Over the following three decades, researchers increasingly recognized that internal opioid pathways regulate not only physical pain but also psychological pain, social attachment, reward processing, emotional suffering, and stress resilience. Neuroimaging studies also identified abnormalities within endogenous opioid systems among depressed patients.

Meanwhile, a separate revolution unfolded. In 2000, John Krystal and Yale colleagues demonstrated that a single subanesthetic ketamine infusion could produce rapid antidepressant effects. Subsequent studies showed equally rapid reductions in hopelessness, anhedonia, and suicidal ideation, which appeared disproportionately greater than their antidepressant effects.

A turning point occurred in 2018 after Schatzberg and Stanford colleagues reported that the opioid-blocking naltrexone attenuated ketamine's antidepressant response. The finding suggested endogenous opioid activation might be necessary for at least part of ketamine's therapeutic effect. Suddenly, the ketamine story and the opioid story were no longer separate narratives.

Interest in opioid systems has reemerged as suicide research moved beyond the assumption that suicidal ideation invariably stems from depression and is its most severe manifestation. Suicidal ideation may continue despite improvements in mood and often fluctuates independently of depression ratings. Many suicidal patients describe a mental state defined by unbearable emotional pain, suffering, anhedonia, social disconnection, hopelessness, and inability to imagine future relief. Edwin Shneidman termed this “psychache,” noting that it represented a common pathway to suicide.

Suicide Essential Reads

The Suicides We're Not Counting

Gambling Disorder Shown to Put People at Risk for Suicide

Increasingly, investigators view suicidality as involving neurobiological processes centering on emotional pain, reward deficiency, attachment disruption, and hopelessness.

Remarkably, these same functions are the ones regulated by endogenous opioid systems—neuropeptides produced by the body. Endogenous opioids help people endure distress while continuing motivation, social bonds, and the expectation that future rewards remain attainable. But if these systems become dysregulated, the resulting experience resembles a state many suicidal individuals describe: emotional pain without relief, diminished reward sensitivity, social isolation, and loss of desire to continue struggling.

When the Ketamine Story Met the Opioid Story

The opioid hypothesis began to reemerge clinically in 1995 when Alex Bodkin and Harvard colleagues reported that buprenorphine, an opioid, improved symptoms in patients with severe treatment-resistant depression.

Buprenorphine activates opioid receptors only partially, producing some beneficial effects of opioid signaling while limiting many effects associated with full opioid agonists. It also antagonizes kappa opioid receptors, dampening dynorphin-mediated stress signaling that has been implicated in dysphoria, anhedonia, and psychological distress—the brain’s response to stress and psychological pain. This is a mechanism that may be particularly relevant to depression, hopelessness, and suicidal thinking.

Naturally, concerns regarding abuse liability of using an opioid limited enthusiasm for this approach. Nevertheless, the study reminded the field that opioids could improve mood in at least some patients with refractory depression.

Suicidal Reversal Hypothesis

Source: Mark Gold, MD with permission

The new Stanford findings become particularly interesting when viewed within a broader neurobiological framework. The model proposes that suicidal thinking emerges from three interacting processes: emotional pain, reward and attachment loss, and the progressive encoding of experience as futile. Over time, the brain increasingly interprets efforts to reverse this state as hopeless, and suicidal ideation becomes more unrelenting.

Opioid system dysfunction may not explain all suicidality, but may represent a central biological substrate for a subtype characterized by psychache, hopelessness, and reward-system collapse.

Recent translational research provides an intriguing example. When investigators repeatedly exposed zebrafish to inescapable challenges, they observed the emergence of a state resembling learned helplessness. Whole-brain imaging identified a norepinephrine-regulated astroglial network which appeared to encode the expectation of futility—the belief that further effort was pointless. Ketamine rapidly reversed this state, restoring active escape behavior despite unchanged circumstances.

Whether analogous mechanisms contribute to human hopelessness remains unknown, but the findings offer a provocative framework for understanding how expectations of futility may operate in humans. Ketamine’s therapeutic effects may extend beyond mood elevation, restoring the capacity to act despite perceived futility.

Viewed this way, Schatzberg's combined drug strategy is elegant. Buprenorphine appears to reduce psychache, dysphoria, stress sensitivity, and anhedonia, and make perseverance emotionally tolerable. Ketamine may restore the capacity to continue struggling, while buprenorphine reduces the emotional pain, making continued effort bearable.

Risk vs. Benefit

Is it ethical to expose suicidal patients to an opioid like buprenorphine? If a four-week course of ultra-low-dose buprenorphine prevents relapse of suicidal ideation during the highest-risk period after ketamine treatment, the benefits may outweigh the risks. Ultimately, the ethical question is remarkably similar to those raised by ECT in the 1940s and by ketamine in the 2000s.

Conclusion

Schatzberg's remarkable study may do more than introduce a new drug combination for treating suicidality. It may revive an important idea that psychiatry largely left behind. Nearly 50 years after NIMH investigators proposed endogenous opioid dysfunction contributing to depressive suffering, contemporary research suggests opioid circuits regulate emotional pain, reward, attachment, stress resilience, and desire to continue living.

If suicidality results from the convergence of psychache, hopelessness, reward dysfunction, and loss of perseverance, then ketamine and buprenorphine together may be among the first interventions aimed directly at the biology of suicidal suffering itself.

More broadly, the findings challenge the assumption that suicidal ideation is merely the endpoint of depression and instead involves partially distinct neurobiological mechanisms that might respond to targeted treatment.